Novartis AG stock (CH0012005267): Pharma player focuses on core business and pipeline momentum

Novartis AG is sharpening its focus on innovative medicines after recent portfolio moves and continues to highlight its late?stage pipeline and capital return policy. The article explains the core business model, revenue drivers and why the stock matters for international and US investors.

Novartis AG has positioned itself as a focused global pharmaceuticals group with an emphasis on innovative prescription medicines, ophthalmology and select generics, following several portfolio streamlinings in recent years according to company disclosures and financial publications as of 2025.

In recent communications, Novartis AG has underlined its intention to concentrate resources on higher-margin innovative drugs, productivity initiatives and shareholder returns, while continuing to invest in late-stage clinical programs across oncology, immunology, cardiovascular and neuroscience, according to company strategy presentations and earnings materials published in 2024 and 2025.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Switzerland
• Core markets: Global prescription medicines with strong presence in Europe, the United States and key emerging markets
• Key revenue drivers: Innovative patented drugs in oncology, cardiovascular, immunology and neuroscience, as well as select generics and ophthalmology products
• Home exchange/listing venue: SIX Swiss Exchange (NVS on NYSE as American depositary shares)
• Trading currency: Swiss franc on the primary listing

Novartis AG: core business model

Novartis AG operates a research-driven pharmaceuticals model built around discovering, developing and commercializing prescription medicines across multiple therapeutic areas, leveraging internal R&D capabilities, targeted business development and collaborations with academic and biotech partners as described in company reports and presentations as of 2024.

The group has historically combined innovative branded drugs with a broad generics and biosimilars offering, while in recent years it has prioritized a more focused portfolio centered on higher-value patented assets and specialty indications, according to strategic updates available in 2023 and 2024.

Novartis AG’s commercial model typically relies on specialist sales forces addressing oncologists, cardiologists, neurologists and other specialists, alongside market access and health economics teams that work with payers and healthcare systems to secure reimbursement in key markets such as the United States and Europe, as described in corporate materials and analyst commentary around 2024.

In addition, the company emphasizes lifecycle management for key products, including label expansions into new indications, pediatric studies and geographic rollouts, in order to sustain revenue contribution from successful launches over longer periods, according to management remarks in earnings presentations and investor events through 2024.

As large pharmaceutical players face patent expiries and pricing scrutiny, Novartis AG’s business model also incorporates disciplined capital allocation, where management balances investment in R&D and business development with dividends and share repurchases, a policy framework that has been outlined in past capital markets communications and annual reports as of 2023 and 2024.

Main revenue and product drivers for Novartis AG

Novartis AG generates a substantial portion of its revenue from innovative medicines in oncology, cardiovascular and immunology, with a focus on targeted therapies and biologics, according to segment breakdowns and product discussions in annual and quarterly reports published up to 2024.

The company’s oncology franchise includes targeted therapies and cell-based treatments that address hematologic malignancies and solid tumors, which have been highlighted as significant growth contributors in recent reporting periods through 2023 and 2024 based on sales commentary and pipeline updates.

Cardiovascular and metabolic therapies also represent important pillars for Novartis AG, with products that seek to address heart failure, hypercholesterolemia and related conditions, and management has described these as key growth vectors in medium-term strategy discussions captured in investor briefing materials as of 2024.

In immunology and neuroscience, Novartis AG markets treatments for conditions such as multiple sclerosis, psoriasis and certain rheumatologic diseases, building on biologics and small molecules that offer differentiated efficacy or dosing profiles, according to therapeutic area overviews in company publications around 2024.

The company’s portfolio additionally includes ophthalmology products, including therapies for retinal diseases, which provide recurring revenue streams and are often supported by long-term treatment regimens, as highlighted in specialist product briefings and investor-day documents during 2023 and 2024.

While innovator drugs account for the majority of sales and earnings, Novartis AG maintains exposure to generics and biosimilars through select operations, which can be more sensitive to price competition but may deliver volume-driven growth, a dynamic frequently discussed in management commentary and sector research notes as of 2024.

Geographically, the United States represents a major revenue and profit contributor for Novartis AG, given higher pricing levels and the importance of the US pharmaceutical market, while Europe, Japan and key emerging markets such as China also provide substantial demand, as indicated by regional segments in annual reports through 2024.

In addition to marketed products, the late-stage pipeline is a critical driver of the company’s medium-term outlook, with management pointing to multiple Phase 3 and registration-stage programs in oncology, cardiovascular and immunology as potential future growth engines in investor presentations as of 2024.

Why Novartis AG matters for US investors

Novartis AG is relevant for US investors not only because its American depositary shares trade on the New York Stock Exchange, but also because the United States is one of the most significant markets for its innovative medicines, influencing pricing, reimbursement and launch dynamics, as explained in corporate filings and exchange information available through 2024.

For diversified US portfolios, Novartis AG can provide exposure to global pharmaceutical trends, including biologics, cell therapies and specialty medicines, which often show different economic cycles compared with more cyclical sectors like energy or industrials, a point frequently underlined in sector analyses and multi-asset strategy pieces as of 2024.

Moreover, developments in US healthcare policy, such as drug pricing discussions, Medicare negotiations and regulatory frameworks for biosimilars, can directly affect Novartis AG’s revenue and profitability, making US policy news an important monitoring point for investors who follow the stock, according to policy-focused research and healthcare industry commentary in 2023 and 2024.

Currency movements between the US dollar and the Swiss franc also matter for US-based shareholders, since the primary reporting currency is the Swiss franc and dividends are typically declared in that currency, which can impact the effective return when translated into US dollars, as discussed in income-focused investment commentary and company dividend documentation through 2024.

Conclusion

Novartis AG stands as a large, research-focused pharmaceutical group with a portfolio concentrated in oncology, cardiovascular, immunology, neuroscience and ophthalmology, backed by a significant late-stage pipeline and a history of capital returns to shareholders through dividends and buybacks, according to company communications through 2024. The company’s strategic emphasis on innovative, higher-margin medicines and portfolio simplification places it squarely in the global trend toward specialty and precision therapies, while maintaining a foothold in generics and biosimilars where scale and cost competitiveness are key. For US investors, the stock offers exposure to global healthcare demand and US drug market dynamics, but it is also subject to regulatory, pricing, patent and currency risks that can affect earnings and valuation over time. This article provides a high-level overview of the business and revenue drivers without constituting any form of investment recommendation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.